- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer
Experts explore the efficacy and safety profiles of elacestrant, an oral selective estrogen receptor degrader (SERD), and other options for endocrine therapy. The panelists also discuss clinical trial insights, progression-free survival rates, and tolerability, highlighting outcomes and advances in metastatic breast cancer treatment.
EP: 1.Evolution of Endocrine Therapies in ER+/HER2– Metastatic Breast Cancer
EP: 2.Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer
EP: 3.Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles
EP: 4.ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer
EP: 5.Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer
EP: 6.Elacestrant: Treatment Considerations, Including Dosing and Compliance
EP: 7.Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life
EP: 8.Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer
EP: 9.Overview of ESR1 Mutations in ER+/HER2- Metastatic Breast Cancer
EP: 10.Best Practices for ESR1 Mutation Testing in Patients With Breast Cancer
EP: 11.The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer
EP: 12.Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer
EP: 13.Research Landscape: Endocrine Therapies for ER+/HER2- Metastatic Breast Cancer
This is a video synopsis/summary of a Peer Exchange featuring Mabel Mardones, MD; Rena Callahan, MD; William Gradishar, MD; and Gregory Vidal, MD, PhD.
Mardones discusses the efficacy and safety of oral SERDs with experts Callahan, Gradishar, and Vidal. Callahan highlights the favorable efficacy of oral elacestrant, which shows double median progression-free survival (PFS) and triple landmark PFS at 1 year compared with standard therapy. Gradishar notes elacestrant’s favorable safety profile, which is well tolerated with minimal dosing adjustments.
Vidal compares elacestrant with fulvestrant, emphasizing elacestrant’s oral administration, superior efficacy––especially in ESR1 mutations––and a similar safety profile. The discussion underscores elacestrant’s promising role in metastatic breast cancer treatment, providing valuable insights for clinicians.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Patient Care Experience Declines After Private Equity Hospital Acquisitions
January 31st 2025Private equity hospital acquisitions in the US were associated with declines in patient care experience, particularly in overall hospital ratings, willingness to recommend, and staff responsiveness.
Read More
